Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
The gene p53 encodes a transcriptional activator of genes involved in growth arrest, DNA repair and apoptosis. Loss of p53 function contributes to tumour development in vivo. The transcriptional activation function of p53 is inactivated by interaction with the mdm2 gene product. Amplification of mdm2 has been observed in 36% of human sarcomas, indicating that it may represent an alternative mechanism of preventing p53 function in tumour development. To study mdm2 function in vivo, we generated an mdm2 null allele by homologous recombination. Mdm2 null mice are not viable, and further analysis revealed embryonic lethality around implantation. To examine the importance of the interaction of MDM2 with p53 in vivo, we crossed mice heterozygous for mdm2 and p53 and obtained progeny homozygous for both p53 and mdm2 null alleles. Rescue of the mdm2-/- lethality in a p53 null background suggests that a critical in vivo function of MDM2 is the negative regulation of p53 activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mdm2 can recruit HDAC1 to p53 to remove these acetylation marks and allow for p53 ubiquitination and degradation [49] in in vitro and mouse models [47,50].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [50]
In the citing paper
“Loss of Mdm2 leads to cell death by apoptosis and embryonic lethality at the blastocyst stage, and this phenotype is completely rescued by concomitant deletion of p53 (Chavez-Reyes, et al., 2003; Jones, et al., 1995; Montes de Oca Luna, et al., 1995).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Montes de Oca Luna, et al., 1995
In the citing paper
“Mouse genetic models strongly suggest that MDM2 and MDMX are the two major p53 antagonists in vivo107,108”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [107]
In the citing paper
“Mouse genetic models strongly suggest that MDM2 and MDMX are the two major p53 antagonists in vivo107,108 and that they exert non-overlapping inhibitory activities towards p53 (Refs 24,109).”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [107]
In the citing paper
“The crucial importance of MDM2 in regulating p53 was demonstrated using Mdm2-null mice, which display very early embryonic lethality (Jones et al., 1995; Montes de Oca Luna et al., 1995).”
From p53 at a glance (2010) · cites this paper as Montes de Oca Luna et al., 1995
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
p53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Thymocyte apoptosis induced by p53-dependent and independent pathways
Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., & Wyllie, A. H. (1993) · Nature · doi:10.1038/362849a0 · Cited by 2,271
Research works printed but not linked: 1
- Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris C. C. Cancer Res. 54, 4855–4878 (1994).
Cited by
Items 801–900 of 1,001
The role of redox environment in neurogenic development
Ostrakhovitch, E. A., & Semenikhin, O. A. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.08.002 · Cited by 32
MDM2 and MDM4 splicing: an integral part of the cancer spliceome
Jeyaraj, S. C., O’Brien, D. M., & Chandler, D. S. (2009) · Frontiers in bioscience · doi:10.2741/3402 · Cited by 37
“The role of MDM2 in the p53 pathway is underscored by the rescue of embryonic lethality in Mdm2 knockout mice by generation in a p53 null background (12, 13).”
BackgroundFukumura, K., Wakabayashi, S., Kataoka, N., Sakamoto, H., Suzuki, Y., Nakai, K., Mayeda, A., & Inoue, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17081153 · Cited by 32
Cetkovská, K., Šustová, H., & Uldrijan, S. (2017) · Scientific Reports · doi:10.1038/srep43180 · Cited by 31
Setting the stage for transformation: HTLV-1 Tax inhibition of p53 function
Cynthia, A. P.-M. (2005) · Frontiers in bioscience · doi:10.2741/1586 · Cited by 32
“The importance of this negative feedback loop is illustrated by the result that MDM2 null mice are not viable unless crossed to p53 null mice (103).”
Backgroundmdm2 mRNA Level is a Prognostic Factor in Soft Tissue Sarcoma
Taubert, H. W., Koehler, T., Meye, A., Bartel, F., Lautenschläger, C., Borchert, S., Bache, M., Schmidt, H., & Würl, P. (2000) · Molecular Medicine · doi:10.1007/bf03401934 · Cited by 31
Does control of mutant p53 by Mdm2 complicate cancer therapy?: Figure 1.
Prives, C., & White, E. P. (2008) · Genes & Development · doi:10.1101/gad.1680508 · Cited by 30
Decreased Mdm2 expression inhibits tumor development induced by loss of ARF
Wang, P., Greiner, T. C., Lushnikova, T., & Eischen, C. M. (2006) · Oncogene · doi:10.1038/sj.onc.1209411 · Cited by 29
“In support of Mdm2’s regulation of p53, deletion of Mdm2 in mice results in an increase in p53 activity and an early embryonic lethality, and loss of p53 rescues this lethality (Jones et al., 1995; Montes de Oca Luna et al., 1995; Received 24 September 2005; revised 20 December 2005; accepted 20 December 2005; publish…”
BackgroundMethodInfluentialMdm2 links genotoxic stress and metabolism to p53
Wang, Z., & Li, B. (2010) · Protein & Cell · doi:10.1007/s13238-010-0140-9 · Cited by 32
Turning the RING Domain Protein MdmX into an Active Ubiquitin-Protein Ligase*
Iyappan, S., Wollscheid, H.-P., Rojas-Fernandez, A., Marquardt, A., Tang, H.-C., Singh, R. K., & Scheffner, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.115113 · Cited by 25
Macchiarulo, A., Giacchè, N., Carotti, A., Baroni, M., Cruciani, G., & Pellicciari, R. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci800146m · Cited by 33
David-Pfeuty, T. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.08.008 · Cited by 37
Rpl27a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models
Terzian, T., Dumble, M. L., Arbab, F., Thaller, C., Donehower, L. A., Lozano, G., Justice, M. J., Roop, D. R., & Box, N. F. (2011) · The Journal of Pathology · doi:10.1002/path.2891 · Cited by 33
“We carried out a closer examination of other p53 pathway mouse models, such as Mdm2 +/− [34], two different loss-offunction alleles of Mdm4: Mdm4 +/− (deletion of part of introns 2–5) [19], Mdm4 +/ 2 (deletion of exon 2) [35], and Mdm2 +/−:Mdm4 +/ 2 mice.”
MethodSelf-citationIdentification of a tumor-derived p53 mutant with novel transactivating selectivity
Pan, Y., & Haines, D. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203663 · Cited by 32
“The protein product of the MDM2 gene is a natural negative regulator of p53 activity (Montes de Oca Luna et al., 1995; Jones et al., 1995) and is oncogenic when overexpressed (Fakharzadeh et al., 1991).”
Backgroundp53 binds the mdmx mRNA and controls its translation
Tournillon, A.-S., López, I., Malbert-Colas, L., Findakly, S., Naski, N., Olivares‐Illana, V., Karakostis, K., Vojtěšek, B., Nylander, K., & Fåhræus, R. (2016) · Oncogene · doi:10.1038/onc.2016.236 · Cited by 33
β-Catenin C-terminal signals suppress p53 and are essential for artery formation
Riascos‐Bernal, D. F., Chinnasamy, P., Cao, L. L., Dunaway, C. M., Valenta, T., Basler, K., & Sibinga, N. E. S. (2016) · Nature Communications · doi:10.1038/ncomms12389 · Cited by 34
p53 Ubiquitination and Proteasomal Degradation
Love, I. M., Shi, D., & Grossman, S. R. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-236-0_5 · Cited by 29
Functional analysis of p53 tumor suppressor in yeast
Šmardová, J., Šmarda, J., & Koptíková, J. (2005) · Differentiation · doi:10.1111/j.1432-0436.2005.00028.x · Cited by 41
MDM2 is a target of simian virus 40 in cellular transformation and during lytic infection
Henning, W., Rohaly, G., Kolzau, T., Knippschild, U., Maacke, H., & Deppert, W. (1997) · Journal of Virology · doi:10.1128/jvi.71.10.7609-7618.1997 · Cited by 29
“Since the mdm2 gene itself is an important target of transcriptional activation by p53 (3, 27, 35, 60, 79), expression of both genes is controlled by an autoregulatory feedback loop (61, 77), and negative regulation of p53 has been shown to be essential for embryonic survival in mice (34, 45).”
BackgroundApoptosis by p53: mechanisms, regulation, and clinical implications
Sionov, R. V., & Haupt, Y. (1998) · Springer Seminars in Immunopathology · doi:10.1007/bf00787230 · Cited by 31
“This tight regulation explains why tumors bearing an amplified Mdm2 tend to retain wt p53 [9, 18], and the dramatic lethality of mdm2 null mice in the presence of wt p53 [ 59 ].”
BackgroundValentin-Vega, Y. A., Box, N., Terzian, T., & Lozano, G. (2009) · Differentiation · doi:10.1016/j.diff.2009.03.001 · Cited by 28
“[PubMed: 12101245] Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2deficient mice by deletion of p53.”
BackgroundSelf-citationTRIMming p53 for ubiquitination
Tai, E., & Benchimol, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905997106 · Cited by 28
“This result is reminiscent of the rescue of embryonic lethality in Mdm2-null mice conferred by loss of p53, a key finding that established the physiological importance of Mdm2 as a negative regulator of p53 (6, 7).”
ResultIn Vitro Selection of Mutant HDM2 Resistant to Nutlin Inhibition
Wei, S. J., Joseph, T., Sim, A. Y. L., Yurlova, L., Zolghadr, K., Lane, D., Verma, C., & Ghadessy, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062564 · Cited by 28
“(DKO) cells (a kind gift from Guillermina Lozano) [26] and H1299 p53 cells [27] were maintained in Dulbecco’s modified”
MethodIt Takes 15 to Tango: Making Sense of the Many Ubiquitin Ligases of p53
Love, I. M., & Grossman, S. R. (2012) · Genes & Cancer · doi:10.1177/1947601912455198 · Cited by 32
“Cementing its status as a critical negative regulator of p53, two simultaneous reports from the Bradley and Lozano groups indicated that mice lacking the Mdm2 gene die during early stages of embryonic development, but that concomitant deletion of p53 results in viable, albeit tumor-prone, mice born at expected Mendeli…”
BackgroundThe neglected part of early embryonic development: maternal protein degradation
Toralová, T., Kinterová, V., Chmelíková, E., & Kaňka, J. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03482-2 · Cited by 37
Shifting the paradigms for tumor suppression: lessons from the p53 field
Barnoud, T., Indeglia, A., & Murphy, M. E. (2021) · Oncogene · doi:10.1038/s41388-021-01852-z · Cited by 31
Ma, W., Tang, F., Xiao, L., Han, S., Yao, X., Zhang, Q., Zhou, J., Wang, Y., & Zhou, J. (2022) · PubMed Central · Cited by 37
Deregulation of cyclin E meets dysfunction in p53: Closing the escape hatch on breast cancer
Barton, M. C., Akli, S., & Keyomarsi, K. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20818 · Cited by 30
“Montes de Oca Luna R, Wagner DS, Lozano G. 1995.”
BackgroundKeePin’ the p53 Family in Good Shape
Mantovani, F., Gostissa, M., Collavin, L., & Sal, G. D. (2004) · Cell Cycle · doi:10.4161/cc.3.7.999 · Cited by 32
D’Orazi, G., Marchetti, A., Crescenzi, M., Coen, S., Sacchi, A., & Soddu, S. (2000) · The Journal of Gene Medicine · doi:10.1002/(sici)1521-2254(200001/02)2:1<52::aid-jgm82>3.0.co;2-4 · Cited by 26
Genetic Modeling of Glioma Formation in Mice
Begemann, M., Fuller, G. N., & Holland, E. C. (2002) · Brain Pathology · doi:10.1111/j.1750-3639.2002.tb00428.x · Cited by 28
p53: Multiple Facets of a Rubik's Cube
Zhang, Y., & Lozano, G. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-121926 · Cited by 28
“Unrestrained p53 activity in the developing embryo through Mdm2 deletion induces apoptosis, resulting in embryonic lethality (Chavez-Reyes et al. 2003, Jones et al. 1995, Montes de Oca Luna et al. 1995).”
BackgroundInfluentialSelf-citationJaiswal, S. K., Oh, J. J., & Depamphilis, M. (2020) · Stem Cells · doi:10.1002/stem.3199 · Cited by 29
“For Mdm2 [59,60] and PACT [61], lethality occurs before embryonic day 7.5, but for Mdm4 [62], lethality occurs by day 10.5.”
BackgroundInfluentialIkonomi, N., Werle, S. D., Schwab, J. D., & Kestler, H. A. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00848 · Cited by 30
“Furthermore, MDM2 expression is triggered by TP53 itself, setting a negative feedback loop in its own regulation (Jones et al., 1995; Montes de Oca Luna et al., 1995; Ringshausen et al., 2006).”
BackgroundTimmerman, D. M., Remmers, T. L., Hillenius, S., & Looijenga, L. H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105377 · Cited by 28
UFL1, a UFMylation E3 ligase, plays a crucial role in multiple cellular stress responses
Jiang, Q., Wang, Y., Xiang, M., Hua, J., Zhou, T., Chen, F., Lv, X., Huang, J., & Cai, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1123124 · Cited by 33
From tumor prevention to therapy: Empowering p53 to fight back
Frezza, C., & Martins, C. P. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.10.001 · Cited by 31
Walter, R. F. H., Mairinger, F. D., Ting, S. C., Vollbrecht, C., Mairinger, T., Theegarten, D., Christoph, D. C., Schmid, K. W., & Wohlschlaeger, J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.27 · Cited by 30
“Overexpression of MDM2 in some tumour types can lead to a loss of P53 regulatory function by increased proteasomal degradation of P53 (Jones et al, 1995; Montes de Oca Luna et al, 1995; Parant et al, 2001; Marine et al, 2006; Ringshausen et al, 2006).”
BackgroundUbiquitin and Ubiquitin-Like Proteins in the Nucleolus: Multitasking Tools for a Ribosome Factory
Shcherbik, N., & Pestov, D. G. (2010) · Genes & Cancer · doi:10.1177/1947601910381382 · Cited by 30
Medina‐Medina, I., García-Beltrán, P., la Mora, I. D. L. M.-D., Oria‐Hernández, J., Millot, G., Fåhræus, R., Reyes‐Vivas, H., Sampedro, J. G., & Olivares‐Illana, V. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00113-16 · Cited by 27
“HDM2(1-354), and HDM2(1-301)] at a concentration of 20 mg/ml in 1”
BackgroundInfluentialEisenberg‐Lerner, A., Ciechanover, A. J., & Merbl, Y. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216651732 · Cited by 29
Stanley-Hasnain, S., Hauck, L., Grothe, D., Aschar‐Sobbi, R., Beca, S., BUTANY, J. W., Backx, P. H., Mak, T. W., & Billia, F. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1346758 · Cited by 29
“embryonic lethality, due to high levels of p53, impairing organ development through extensive apoptosis and diminished cell proliferation.(16,17)”
Backgroundp53 and its isoforms in DNA double-stranded break repair
Zhang, Y., Pan, W., & Chen, J. (2019) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1900167 · Cited by 28
Alternative product of the p16/CKDN2A locus connects the Rb and p53 tumor suppressors
James, M. C., & Peters, G. G. (2000) · Springer eBooks · doi:10.1007/978-1-4615-4253-7_7 · Cited by 31
Zeng, X., Keller, D., Wu, L., & Lu, H. (2000) · PubMed · Cited by 35
Constitutive mdmx Expression During Cell Growth, Differentiation, and DNA Damage
Jackson, M. W., & Berberich, S. J. (1999) · DNA and Cell Biology · doi:10.1089/104454999314971 · Cited by 27
“For example, mouse embryos lacking Mdm-2 fail to develop beyond day 6 of gestation but are viable if also lacking p53 (Jones et al ., 1995; Montes de Oca Luna et al ., 1995).”
Biderman, L., Poyurovsky, M. V., Assia, Y., Manley, J. L., & Prives, C. L. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06150-11 · Cited by 30
Inhibition of Nutlin-Resistant HDM2 Mutants by Stapled Peptides
Wei, S. J., Joseph, T. L., Chee, S. M. Q., Li, L., Yurlova, L., Zolghadr, K., Brown, C. J., Lane, D. P., Verma, C. S., & Ghadessy, F. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081068 · Cited by 27
MYL6B, a myosin light chain, promotes MDM2-mediated p53 degradation and drives HCC development
Xie, X., Wang, X., Liao, W., Fei, R., Wu, N., Xu, C., Chen, Q., Wei, L., Wang, Y., & Chen, H. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0693-7 · Cited by 27
“Many studies have shown that the most predominant function of MDM2 is to down regulate the stabilization of p53 protein and its’ downstream pathway [4].”
High levels of Hdmx promote cell growth in a subset of uveal melanomas.
de Lange, J., Teunisse, A. F. A. S., Vries, M. V., Lodder, K., Lam, S., Luyten, G. P. M., Bernal, F., Jager, M. J., & Jochemsen, A. G. (2012) · Europe PMC (PubMed Central) · Cited by 30
Goh, A. M., Xue, Y., Leushacke, M., Li, L., Wong, J. S., Chiam, P. C., Rahmat, S. A. B., Mann, M. B., Mann, K. M., Barker, N., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4956 · Cited by 28
“The target genes of p53 include Mdm2, which targets p53 for proteasomal degradation, enabling an important negative feedback loop that restores the low basal levels of p53 after activation [2-6].”
BackgroundSelf-citationLam, S., Wiercinska, E., Teunisse, A. F. A. S., Lodder, K., ten Dijke, P., & Jochemsen, A. G. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3147-8 · Cited by 29
“Mdm2 and Mdmx are non-redundant critical regulators of p53 stability and activity [2–6].”
BackgroundPKB/Akt activation inhibits p53‐mediated HIF1A degradation that is independent of MDM2
Choy, M., Movassagh, M., Bennett, M. R., & Foo, R. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21980 · Cited by 28
Integration of the PRB and P53 Cell Cycle Control Pathways
Stewart, C. L., Soria, A. M., & Hamel, P. A. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1010615822317 · Cited by 31
p53 and the CNS: Tumors and developmental abnormalities
Fulci, G., & Meir, E. G. V. (1999) · Molecular Neurobiology · doi:10.1007/bf02741378 · Cited by 29
“The delay between p53 induction and MDM2 activation defines the time during which p53 can exert its activity (49,50).”
BackgroundThe p53 Tumor Suppressor Inhibits Transcription of the TATA-less Mouse DP1 Promoter
Gopalkrishnan, R. V., Lam, E. W. ‐., & Kédinger, C. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.18.10972 · Cited by 29
Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability
Lü, Y., Cho, T., Mukherjee, S., Suarez, C. F., Foutel, N. S. G., Malik, A., Martinez, S., Dervovic, D., Oh, R. H., Langille, E. R., et al. (2024) · Molecular Systems Biology · doi:10.1038/s44320-024-00032-x · Cited by 31
PROTAC: Novel degradable approach for different targets to treat breast cancer
Wang, Z., Che, S., & Yu, Z. (2024) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2024.106793 · Cited by 26
MDM2 Controls the Timely Expression of Cyclin A to Regulate the Cell Cycle
Frum, R. A., Ramamoorthy, M., Mohanraj, L., Deb, S., & Deb, S. P. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0334 · Cited by 26
“Normal, p53−/−, and p53−/− MDM2−/− MEF cells derived from isogenic mice were kind gifts from Guillermina Lozano (32), and were cultured in DMEM in the presence of 10% fetal bovine serum.”
MethodInfluentialBehind the scenes: Unravelling the molecular mechanisms of p53 target gene selectivity (Review)
Lohrum (2010) · International Journal of Oncology · doi:10.3892/ijo_00000757 · Cited by 30
“Homozygous deletion of MDM2 is lethal in mice due to p53-mediated apoptosis during early embryogenesis, while deletion of both MDM2 and p53 gives rise to mice that develop normally, demonstrating the importance of MDM2 in regulating p53 activation (33,34).”
BackgroundUsing Mouse Models to Explore MDM-p53 Signaling in Development, Cell Growth, and Tumorigenesis
Gannon, H., & Jones, S. N. (2012) · Genes & Cancer · doi:10.1177/1947601912455324 · Cited by 27
“These developmental defects were due to unregulated p53 activity in the embryo, as concomitant knockout of p53 completely rescued the early developmental lethality of Mdm2-null mice.(32,33) These results clearly documented a critical role for Mdm2dependent regulation of p53 during development.”
BackgroundMethodSurvival Signalling in the Preimplantation Embryo
O’Neill, C., Li, Y., & Jin, X. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-2480-6_5 · Cited by 27
Overproduction of MDM2 in vivo disrupts S phase independent of E2F1.
Reinke, V., Bortner, D. M., Amelse, L. L., Lundgren, K., Rosenberg, M. P., Finlay, C. A., & Lozano, G. (1999) · PubMed · Cited by 31
Self-citationOddball p53 in testicular tumors
Chresta, C. M., & Hickman, J. A. (1996) · Nature Medicine · doi:10.1038/nm0796-745 · Cited by 26
Mdm2 Regulates p53 Independently of p19ARF in Homeostatic Tissues
O'Leary, K. A., Mendrysa, S. M., Vaccaro, A., & Perry, M. E. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.1.186-191.2004 · Cited by 25
“In contrast, activation of these same pathways in homeostatic, nontumorigenic cells can have undesired consequences, including organ atrophy (11) or, in the extreme, embryonic lethality (6, 13).”
BackgroundPopulation distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649)
Knappskog, S., Gansmo, L. B., Dibirova, K., Metspalu, A., Cybulski, C., Peterlongo, P., Aaltonen, L. A., VATTEN, L. J., Romundstad, P., Hveem, K., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1910 · Cited by 26
“The importance of MDM2 function is illustrated by the fact that Mdm2 knock-out leads to early embryonic death in mice, which can be reversed by concomitant knockout of the TP53 gene [3, 4].”
BackgroundMairinger, F. D., Werner, R., Flom, E., Schmeller, J., Borchert, S., Wessolly, M., Wohlschlaeger, J., Hager, T., Mairinger, T., Kollmeier, J., et al. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2133-z · Cited by 26
Jeffers, J. R., Pinto, E. M., Rehg, J. E., Clay, M. R., Wang, J., Neale, G. A. M., Heath, R. J., Lozano, G., Lalli, E., de Figueiredo, B. C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1750 · Cited by 25
Self-citationMdm2 protein Expression is Strongly Associated with Survival in Malignant Pleural Mesothelioma
Mairinger, F. D., Walter, R. F. H., Ting, S. C., Vollbrecht, C., Kollmeier, J., Griff, S., Hager, T., Mairinger, T., Christoph, D. C., Theegarten, D., et al. (2014) · Future Oncology · doi:10.2217/fon.13.261 · Cited by 27
Mdm2 exerts pro-apoptotic activities by antagonizing insulin-like growth factor-I-mediated survival
Froment, P., Dupont, J., & Marine, J. (2008) · Cell Cycle · doi:10.4161/cc.7.19.6807 · Cited by 27
The pathway regulating MDM2 protein degradation can be altered in human leukemic cells.
Pan, Y., & Haines, D. S. (1999) · PubMed · Cited by 29
Mdm2 Regulates Estrogen Receptor and Estrogen-responsiveness in Breast Cancer Cells
Kim, K., Burghardt, R. C., Barhoumi, R., Lee, S., Liu, X., & Safe, S. H. (2010) · Journal of Molecular Endocrinology · doi:10.1677/jme-10-0110 · Cited by 29
Li, Z., & Xiong, Y. (2017) · Oncogene · doi:10.1038/onc.2017.141 · Cited by 25
Davoodi, P., Srinivasan, M. P., & Wang, C. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb00481h · Cited by 25
DNAJB1 stabilizes MDM2 and contributes to cancer cell proliferation in a p53-dependent manner
Qi, M., Zhang, J., Zeng, W., & Chen, X. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.12.003 · Cited by 26
Staples, O. D., Steele, R. J., & Laín, S. (2008) · The Surgeon · doi:10.1016/s1479-666x(08)80034-0 · Cited by 25
MDM2 Splice Variants and Their Therapeutic Implications
Harris, L. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332654 · Cited by 24
Mdm2 Inhibits the Apoptotic Function of p53 Mainly by Targeting It for Degradation
Yap, D., Hsieh, J.-K., & Lü, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004359200 · Cited by 24
P53 null mice: damaging the hypothesis?
Sansom, O. J., & Clarke, A. R. (2000) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(00)00089-0 · Cited by 29
“[35] R.”
BackgroundMDM2-Mediated Degradation of p14ARF: A Novel Mechanism to Control ARF Levels in Cancer Cells
Vivo, M., Matarese, M., Sepe, M., Martino, R. D., Festa, L., Calabrò, V., Mantia, G. L., & Pollice, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117252 · Cited by 27
Guilty as CHARGED: p53's expanding role in disease
Van Nostrand, J. L., & Attardi, L. D. (2014) · Cell Cycle · doi:10.4161/15384101.2014.987627 · Cited by 23
“These observations provided the first demonstration that unrestrained p53 activity during development can drive embryonic lethality.(13,15,16) Similarly, Mdmx¡/¡ mice are Keywords: p53, transcriptional activation, CHARGE syndrome, CHD7, embryonic development, Ribosomopathy, Mdm2, neural Crest”
BackgroundStructural basis of how stress-induced MDMX phosphorylation activates p53
Chen, X., Gohain, N., Zhan, C., Lu, W.-Y., Pazgier, M., & Lu, W. (2015) · Oncogene · doi:10.1038/onc.2015.255 · Cited by 22
Cell death and morphogenesis during early mouse development: Are they interconnected?
Bedzhov, I., & Zernicka‐Goetz, M. (2015) · BioEssays · doi:10.1002/bies.201400147 · Cited by 23
“genes, rescuing the double knockout embryos [37, 38].”
Chua, J. S., Liew, H. P., Guo, L., & Lane, D. P. (2015) · Oncogene · doi:10.1038/onc.2015.57 · Cited by 25
Bittenbring, J. T., Parisot, F., Wabo, A., Monika, M., Kerschenmeyer, L., Kreuz, M., Trümper, L. H. P., Landt, O., Menzel, A., Pfreundschuh, M. G., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-116 · Cited by 26
“For example, reduction of MDM2 expression in mice reduces adenoma formation [2] whereas MDM2 deficiency causing overshooting p53 activity was reported to be lethal [3,4].”
BackgroundYan, S., Qiu, L., Ma, K., Zhang, X., Zhao, Y., Zhang, J., Li, X., Hao, X., & Li, Z. (2013) · Oncogene · doi:10.1038/onc.2013.494 · Cited by 25
Autoactivation of the MDM2 E3 Ligase by Intramolecular Interaction
Cheng, Q., Song, T., Chen, L., & Chen, J. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00246-14 · Cited by 27
“Mouse models provided strong evidence that MDM2 is indispensable for controlling p53 activity at all stages of life (4-6).”
BackgroundPeli1 Modulates the Subcellular Localization and Activity of Mdmx
Li, D., Tavana, O., Sun, S., & Gu, W. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3531 · Cited by 22
“The critical roles of Mdm2 and Mdmx in regulating p53 are best demonstrated by studies carried out in mice where inactivation of p53 was shown to completely rescue the embryonic lethality caused by the loss of either Mdm2 or Mdmx (11, 12).”
BackgroundLoss of SET reveals both the p53-dependent and the p53-independent functions in vivo
Kon, N., Wang, D., & Gu, W. J. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1484-6 · Cited by 22
The roles of mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A review
Jiang, H., Luo, J., & Lei, H. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2021.108910 · Cited by 23
Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice
Iwakuma, T., Parant, J. M., Fasulo, M., Zwart, E., Jacks, T., de Vries, A., & Lozano, G. (2004) · Oncogene · doi:10.1038/sj.onc.1207793 · Cited by 27
“Genotypes for mdm2, mdm4, and p53 alleles were performed according to published studies (Jacks et al., 1994; Montes de Oca Luna et al., 1995; Parant et al., 2001).”
BackgroundMethodInfluentialSelf-citationMétay, C., Mir, L. M., Carlier, K., Lécluse, Y., Tétaud, C., Mishal, Z., & Wiels, J. (2001) · Blood · doi:10.1182/blood.v97.4.1043 · Cited by 24
HDM2 promotes WIP1-mediated medulloblastoma growth
Buss, M. C., Read, T., Schniederjan, M., Gandhi, K., & Castellino, R. C. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos001 · Cited by 28
“Absence of Mdm2 expression is known to result in death of mice in utero because of Trp53-mediated apoptosis; lethality can be fully rescued by deletion of the Trp53 gene.(53,54) A recent study using mice that express a hypomorphic allele of Mdm2, Mdm2 found that a 70% reduction in expression of Mdm2 protein results in…”
BackgroundPeptide Activators of the p53 Tumor Suppressor
Zhan, C., & Lu, W. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222577 · Cited by 23
Recent progress and open challenges in modeling p53 dynamics in single cells
Batchelor, E., & Loewer, A. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.04.007 · Cited by 23
Rempe, D. A., Lelli, K. M., Vangeison, G., Johnson, R. S., & Federoff, H. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702203200 · Cited by 28
Dissecting p53 tumor suppressor function in vivo through the analysis of genetically modified mice
Johnson, T. M., & Attardi, L. D. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401902 · Cited by 26
Gorgoulis, V. G., Zacharatos, P., Manolis, E. N., Ikonomopoulos, J., Damalas, A., Lamprinopoulos, C., Rassidakis, G. Z., Zoumpourlis, V. C., Kotsinas, A., Rassidakis, A., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.60 · Cited by 23
Developmental Acquisition of p53 Functions
Jaiswal, S. K., Raj, S., & Depamphilis, M. (2021) · Genes · doi:10.3390/genes12111675 · Cited by 25
Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program
Gencel‐Augusto, J., Su, X., Qi, Y., Whitley, E. M., Pant, V., Xiong, S., Shah, V. V., Lin, J., Perez, E., Fiorotto, M. L., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0872 · Cited by 25
Self-citation
Metadata
- Authors
- de Oca Luna, R. M., Wagner, D. S., & Lozano, G.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Venue
- Nature
- Published
- 1995-11
- Volume
- 378
- Issue
- 6553
- Pages
- 203-206
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1969044026
- Semantic Scholar
- e682601f6b2b8de8fa63cc39518a1461943483bc
- Cited by
- 1,420
- References
- 29
- Citations by year
- 2026: 10 · 2025: 24 · 2024: 31 · 2023: 30 · 2022: 31 · 2021: 32 · 2020: 49 · 2019: 29 · 2018: 32 · 2017: 49 · 2016: 63 · 2015: 44 · 2014: 67 · 2013: 37 · 2012: 63
- FWCI
- 15.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p53, MDM2, embryonic lethality, p53-MDM2 interaction, tumor suppressor, sarcoma, homologous recombination, DNA repair
- MeSH terms
- Animals, Base Sequence, Cell Line, Crosses, Genetic, Female, Genes, Lethal, Heterozygote, Homozygote, Male, Mice, Inbred C57BL, Molecular Sequence Data, Nuclear Proteins, Proto-Oncogene Proteins, Tumor Suppressor Protein p53, Gene Deletion, DNA Primers, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.